|
Acquired antithrombin III deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Acquired antithrombin III deficiency: replacement with antithrombin III concentrates in a patient with protein S deficiency accelerates response to therapy.
|
8291376 |
1993 |
|
Acquired thrombophilia
|
0.010 |
Biomarker
|
disease |
BEFREE |
CRVO is associated with familial thrombophilia (factor V Leiden, factor VIII, low antithrombin III, homocysteinemia), and CRAO is associated with familial and acquired thrombophilia (low protein C, homocysteinemia, lupus anticoagulant), providing avenues for thromboprophylaxis, and triggering family screening.
|
18160589 |
2008 |
|
Acth-Independent Macronodular Adrenal Hyperplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients with CD had higher baseline mean cortisol levels, ATIII activity and vWF:Ag levels compared with adrenal CS.
|
28226363 |
2017 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protein C, protein S, antithrombin III, and activated protein C resistance (APCR) were assayed.
|
15309526 |
2004 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has become apparent that RAPC is even more common than deficiencies in protein C, protein S, or antithrombin III (AT-III) and affects an estimated 5% of the general population.
|
8733870 |
1996 |
|
Activated Protein C Resistance
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Functional tests of hemostasis included evaluations of prothrombin time; activated partial thromboplastin time; levels of fibrinogen, serum homocysteine, protein C and S, and antithrombin III; activated protein-C resistance; and dilute Russell viper venom time.
|
12473703 |
2002 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of inherited hypercoagulability in patients with venous thromboembolism includes testing for the functional activity of protein S, protein C, antithrombin III, and for resistance to activated protein C. Resistance to activated protein C can be assessed with plasma as well as with DNA-based assays that are commercially available.
|
9372103 |
1996 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
These include AT-III deficiency, protein C and S deficiencies, and APC resistance.
|
9158617 |
1997 |
|
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found 22 (48%) patients with the SPS, 11 (24%) with the aPCR phenotype, 5 (11%) with the factor V Leiden mutation, 7 (15%) with the prothrombin gene mutation, 29 (63%) with the MTHFR gene mutation, 11 (24%) with the factor V HR2 haplotype, 11 (24%) with antiphospholipid antibodies, 4 (9%) with PS deficiency, 6 (13%) with PC deficiency, one with the FV Hong Kong mutation, and one with AT-III deficiency.
|
15609280 |
2005 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fifty six young patients (age <45 yr) with doppler-proven DVT were investigated for the presence of resistance to activated protein C (APC-R), lupus anticoagulant (LA), anticardiolipin antibodies and deficiencies of protein C, protein S, ATIII activities.
|
10414451 |
1999 |
|
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We detected methylenetetrahydrofolate reductase (MTHFR) A1298C, MTHFR C677T, factor V Leiden, PAI-1, mutant prothrombin G20210A, plasma homocysteine, antithrombin III, protein S and activated protein C resistance.
|
20868443 |
2010 |
|
Activated Protein C Resistance
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activated protein C resistance and protein C and antithrombin III levels were determined in women (n = 50) with a history of preeclampsia and in controls (50 women with a previous normal pregnancy).
|
9065198 |
1997 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
APC resistance (13.4 %) was detected to be most common in Indian RPL patients followed by PS (10.6 %), PC (9.8 %) and AT deficiency (4.31 %.).
|
25771983 |
2015 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nine out of fourteen subjects showed APC-resistance but no deficiencies in the anticoagulant proteins AT III, PC and PS.
|
9555645 |
1997 |
|
Activated Protein C Resistance
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The following laboratory tests were performed: prothrombin time, partial thromboplastin time, fibrinogen levels, antithrombin III, plasmatic fibronectin (as a marker of endothelial damage), haptoglobin (as a marker of intravascular haemolysis), a functional test for APC-R and analysis of factor V Leiden mutation by polymerase chain reaction.
|
12571435 |
2002 |
|
Acute Coronary Syndrome
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Although intravenous heparin is routinely used in the treatment of patients with acute coronary syndromes, this anticoagulant requires antithrombin III as a cofactor, has no affinity to clot-bound thrombin, and is bound or inactivated by several plasma proteins and platelet factor 4.
|
7923645 |
1994 |
|
Acute lymphocytic leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
A novel ATIII isoform pattern which was observed in 4/80 children with acute lymphatic leukaemia (ALL) and in 1/4 children with Ewing's sarcoma, has been shown by family studies to be due to a mutant form of ATIII (AT Dublin) in the heterozygous state.
|
3472589 |
1987 |
|
Acute lymphocytic leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
ASP and ATIII activity was measured in 76 children with ALL treated according to the ALL IC BFM 2002 protocol.
|
28060110 |
2017 |
|
Acute myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
AMI complicated with cerebral infarction has negative correlations with the levels of AT-III and adiponectin, but positively associated with the levels of NT-proBNP, HOMA-IR and HMGB1, possessing certain clinical significance in AMI treatment.
|
31173318 |
2019 |
|
Acute pancreatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Conclusion ATIII and protein C levels decreased as severity of AP increased, particularly in cases of biliary AP.
|
28222624 |
2017 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ASP and ATIII activity was measured in 76 children with ALL treated according to the ALL IC BFM 2002 protocol.
|
28060110 |
2017 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among these, 14 genes (FTL, K-ALPHA1, LDHA, RPL4, ENO1, ANXA2, RPL9, RPL10, RPL13A, GNB2L1, AMBP, GC, A1BG, and SERPINC1), in addition to previously well-known liver cancer related genes, were confirmed to be differentially expressed in seven liver cancer cell lines and 17 HCC tissues by semi-quantitative RT-PCR.
|
16820872 |
2006 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest the increased presence of ATIII commensurate with astrogliosis and association with the neurofibrillary pathology of AD.
|
8362984 |
1993 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We conclude that in concert with other amyloid-associated serine protease inhibitors, ATIII may play a role in the pathogenesis of cerebral amyloidosis.
|
8362984 |
1993 |
|
Anterior myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
AMI complicated with cerebral infarction has negative correlations with the levels of AT-III and adiponectin, but positively associated with the levels of NT-proBNP, HOMA-IR and HMGB1, possessing certain clinical significance in AMI treatment.
|
31173318 |
2019 |